CVS Health vs UnitedHealth CVS vs UNH
CVS Health and UnitedHealth on one sheet: valuation multiples, growth, margins, debt, dividends and returns, each section labelled with the period it covers, from the companies' filings. Add or remove a stock above the sheet; the link holds the set.
What differs most
- Market value: UnitedHealth $368.64B, CVS Health $118.34B.
- Net margin: UnitedHealth 3.5%, CVS Health 1.2%.
- Price / sales: UnitedHealth 0.8×, CVS Health 0.3×.
- Return on equity: UnitedHealth 15.3%, CVS Health 6.2%.
Price return
2025-10-26 → 2026-10-26
CVS+12.9%
UNH+13.3%
Profile
latestSector
Healthcare
Healthcare
Industry
Medical - Healthcare Plans
Medical - Healthcare Plans
Market value
$118.34B
$368.64B
Enterprise value
$183.32B
$417.13B
Employees
259,500
390,000
Revenue per employee (TTM)
$1.6M
$1.2M
Our models
nightlythe valuation on each stock's pagePrice vs model
5% overvalued vs model
31% overvalued vs model
Model range
$28.63–238
$182–845
Models in the headline
1
1
FCF growth priced in, at a 10% return
14.1%
14.3%
Every model, its assumptions and its range: CVS valuation · UNH valuation. The growth priced in, at any return: CVS reverse DCF · UNH reverse DCF.
Trading
close 2026-10-26Last close
$92.53
$410.70
52-week high
$110.60
$436.35
52-week low
$70.08
$259.02
Price vs 52-week high
−16.3%
−5.9%
Price vs 52-week low
+32.0%
+58.6%
Average daily volume / shares
0.6%
0.6%
Beta
0.60
0.61
Returns
to 2026-10-261 month
+3.8%
+9.1%
3 months
−14.1%
−2.4%
6 months
+18.7%
+15.7%
Year to date
+16.6%
+24.4%
1 year
+12.9%
+13.3%
1 year, dividends added
+16.2%
+15.8%
2 years
+63.8%
−27.3%
Valuation
CVS price × TTM to Jun 2026 · UNH price × TTM to Sep 2026P/E (TTM)
24.4×
23.4×
P/E on consensus EPS (next FY)
11.5×
20.0×
Price / sales
0.3×
0.8×
EV / sales
0.4×
0.9×
EV / EBITDA
13.7×
14.9×
Price / book
1.5×
3.5×
Price / free cash flow (FY)
15.2×
22.9×
Free-cash-flow yield (FY)
6.6%
4.4%
Growth
TTM and FY2025Revenue growth (TTM)
—
—
Revenue growth, consensus next FY
+3.7%
+0.1%
Revenue, 3-year CAGR
7.6%
11.4%
Revenue, 5-year CAGR
8.4%
11.7%
EPS growth (TTM)
—
—
EPS growth, consensus next FY
+479.0%
+55.5%
EPS, 3-year CAGR
−24.7%
−14.5%
Free cash flow, 3-year CAGR
−16.6%
−11.8%
Diluted shares, 3-year change
−3.9%
−4.2%
Profitability
CVS TTM to Jun 2026 · UNH TTM to Sep 2026Gross margin (FY)†
13.8%
18.5%
Operating margin
3.4%
5.3%
EBITDA margin
3.2%
6.2%
Net margin
1.2%
3.5%
Free-cash-flow margin (FY)
1.9%
3.6%
Return on equity
6.2%
15.3%
Return on assets
1.9%
5.1%
Asset turnover
1.64
1.44
† Gross margin (FY): As filed. Companies draw the cost-of-revenue line in different places, so gross margins of two companies in one industry can differ for that reason alone; operating margin does not depend on where the line is drawn.
Balance sheet
CVS MRQ Jun 2026 · UNH MRQ Sep 2026Cash
$11.33B
$25.84B
Total debt
$76.31B
$74.33B
Net debt
$64.98B
$48.49B
Debt / equity
1.0×
0.7×
Net debt / EBITDA (TTM)
4.8×
1.7×
Interest coverage (FY)
3.3×
4.7×
Current ratio (FY)
0.84
0.79
Dividends
trailing 12 monthsDividend yield
2.9%
2.2%
Dividends per share
$2.66
$9.06
Payout ratio (of TTM EPS)
70.2%
51.6%
Dividend per share, 5-year CAGR
5.9%
10.9%
Frequency
Quarterly
Quarterly
Ownership and activity
last 90 days · latest 13FTracked superinvestors holding (13F)
12
20
Insider open-market buys (Form 4)
$0
$0
Insider sales (Form 4)
$0
$661K
Analyst upgrades
0
0
Analyst downgrades
0
0
Statements
CVS income TTM to Jun 2026 · cash flow FY2025 · UNH income TTM to Sep 2026 · cash flow FY2025Revenue
$415.09B
$449.66B
EBITDA
$13.41B
$27.99B
Operating income
$14.01B
$23.92B
Net income
$4.91B
$15.88B
EPS (diluted)
$3.79
$17.56
Operating cash flow
$10.64B
$19.70B
Capital expenditure
−$2.83B
−$3.62B
Free cash flow
$7.81B
$16.07B
Dividends paid
$3.40B
$7.92B
Statements, prices, dividends and consensus estimates from Financial Modeling Prep; insider trades from Form 4 and holdings from 13F. Refreshed nightly. A comparison of filed numbers, not a recommendation to buy, sell or hold any security.